The aim of the present study was to determine the effect of resveratrol on dipeptidyl peptidase 4 
INTRODUCTION
Diabetes mellitus is a group of metabolic disorders characterized by hyperglycemia, dyslipidemia, and altered protein metabolism. Altered rates of gluconeogenesis are responsible for increased hepatic glucose output and therefore, sustained hyperglycemia in both IDDM and NIDDM A key step in gluconeogenesis is the formation of phosphoenolpyruvate from oxaloacetate, which is catalyzed by phosphoenolpyruvate carboxykinase (PEPCK) enzyme. Augmented activity of PEPCK enzyme contributes to the maintenance of elevated plasma glucose in chemically induced diabetes (3) . Dipeptidyl peptidase-4 (DPP-4, EC 3.4.14.5) exists on the surface of various types of cells, and in a soluble form in plasma. DPP-4 is a serine protease, which cleaves the penultimate L-proline or L-alanine at the N-terminus of several polypeptides, such as glucagon-like peptide 1 (GLP-1) and glucosedependent insulinotropic polypeptide (GIP) (4,5) . These peptides augment nutrient-induced insulin release from pancreatic β-cells. Their cleavage can be blocked by specific DPP-4 inhibitors, resulting in increased plasma concentrations of the intact peptides and improved glucose tolerance (6,7) . Resveratrol is one of naturally occurring phytochemicals produced by a wide diversity of plants such as grapes, peanuts and mulberries. It has a variety of biological and pharmacological effects including anti-inflammatory, antioxidant, anticarcinogenic and cardio-protective activities (8) . It ameliorates common diabetes symptoms, such as polyphagia, polydipsia, and body weight loss. Several studies have shown that resveratrol possesses hypoglycemic and hypolipidemic effects in STZ induced diabetic rats.
(8,9,10) Mechanism of antihyperglycemic effect of resveratrol in STZ-induced diabetic rats is still unclear. So, the aim of the present study was to determine the effect of resveratrol on DPP-4 and PEPCK activities in STZ -induced diabetic rats, to find an explanation for its hypoglycemic effect
MATERIALS & METHODS

Chemicals
Most chemicals including STZ and resveratrol were purchased from Sigma Aldrich Chemical Co., St. Louis, MO, USA, stored at 2-4 •C and protected from sunlight.
Animals 2.1. Experimental animals and diets
This study was carried out on 60 male Wister albino rats of approximately (90 -140 g) body weight. During the study, animals were housed in wire mesh cages and were fed standard rat chew and allowed free access to water. They were kept under constant environmental conditions (25•C and 12 hour dark light cycle). All animals were weighed at the beginning and at the end of the study. (Dead rats were excluded from the study)
Induction of diabetes
Induction of diabetes was made by a single intraperitoneal injection of STZ at a dose of 70 mg/kg body weight in freshly prepared ice-cold citrate buffer (0.1 M pH 4.0) for 3 consecutive days. STZ was used to induce damage to pancreatic beta cells and produce type I diabetes. Diabetes was defined as a blood glucose level greater than 250 mg/dl (11) using a drop of blood obtained by a tail-vein puncture monitored at different time intervals throughout the study using glucocheck method strips (Roche Diagnostics GmbH, Germany).  A third portion was used for histopathological examination. The liver was fixed in neutral buffered formalin solution (10%) and dehydrated in a graded series of ethanol, cleared in xylol and impregnated in soft paraffin for 2 hours at 56 ˚C then embedded in hard paraffin. Sections of 4 μm thickness were cut by the microtome and stained with hematoxylin and eosin (H&E). The tissues were observed using an optical microscope.
Animal treatment
Statistical Analysis
All the data were expressed as mean ± standard deviation (SD). Statistical analysis was done using one-way analysis of variance (ANOVA), and post-hoc comparisons were carried out using Tukey's t-test. The Pearson correlation test was used to find out the correlation between the studied parameters. P values <0.05 were considered as significant. Table (1) shows a comparison between all the studied groups as regard all the studied parameters, in which both serum glucose, DPP-4 activity, and liver PEPCK activity were significantly increased but serum insulin and liver glycogen were significantly decreased in STZ treated group, while upon resveratrol treatment , they were all reversed with no significant difference between group I and group III( except for final fasting serum glucose level) , but final body weight was significantly lower in group II and III than in group I with no significant difference between group II and group III so, diabetic rats treated with resveratrol failed to gain weight in a significant manner as all diabetic rats were smaller than those of control group. Table ( 2) showed that both DPP-4 and PEPCK were significantly positively correlated with serum blood glucose but significantly negatively correlated with serum insulin level. Figure (1 
RESULTS
) shows liver histopathological changes of normal control, with normal hepatocytes and rounded nuclei forming hepatic cell cords radiating from the central vein. Figure (2) shows liver histopathological changes of diabetic rats exhibiting marked fatty degeneration, granular hyaline degeneration, and mild inflammation. Figure (3) shows liver histopathological changes of diabetic rats treated with resveratrol presenting normalization of hepatocytes arrangement around the central vein with declined fat accumulation and decreased central vein dilatation.
Figure (1): Histopathological changes of liver tissue of control group (Group I).
Light microscopical picture of control liver tissue, showing the normal hepatocytes with rounded nuclei forming hepatic cell cords radiating from the central vein.
Figure (2): Histopathological changes of liver of STZ diabetic group (Group II).
Liver tissue of diabetic rat, showing the hypertrophied and vacuolated hepatic cells with heavy cellular infiltration and areas of focal necrosis.
Figure (3): Histopathological assessment of STZ diabetic liver treated with resveratrol (Group III).
Liver tissue of diabetic rat treated with resveratrol showing the apparently normal hepatic cells with few inflammatory cells
DISCUSSION
Pharmacological intervention in diabetes focuses on a series of targets, including -cell function, insulin sensitivity in the muscle, and glucose output in the liver. Many of these hypoglycemic agents showed restricted efficacy and certain adverse effects, therefore, there is a need for phytochemicals that have antihyperglycemic potential and are safe without long-term side effects (18) . In the current study there was a significant increase in fasting serum glucose level but a significant decrease in serum insulin level and liver glycogen in STZ induced diabetic group which was reversed upon resveratrol treatment.
STZ potentially damages the pancreatic β-cells resulting in an apparent decline in insulin levels which is responsible for the decreased liver glycogen levels and subsequently, hyperglycemia (19) . The sustained hyperglycemia may cause reduced number of glucose transporters, down regulation in insulin receptors number as well as defects of tissue insulin signal transduction. Subsequent to these deteriorations, there is an absolute increase in hepatic glucose output, which exceeds an increase of glucose utilization, and fasting hyperglycemia occurs (20) . The glucose-lowering properties of resveratrol in STZinduced diabetic rats in the present study may be due to the direct stimulatory effects of resveratrol on glucose uptake in soleus muscle, adipocytes and hepatocytes, or due to increase in insulin secretion via its effect on the ATP/ADP ratio that induces depolarization of the plasma membrane and triggers insulin secretion revealed that resveratrol could produce a hypoglycaemic effect in insulin-deficient STZ-diabetic rats via phosphatidylinositol-3-kinase (PI3K)-Akt-signaling pathway to enhance glucose uptake into skeletal muscle, also, it may result in an increase in GLUT4 expression in skeletal muscle and a decrease PEPCK expression in the liver. Despite recognition of the critical role that PEPCK exerts in controlling gluconeogenesis in the liver, the validation of this enzyme as a target for pharmacological intervention in diabetes has not been extensively investigated. Therefore, the effect of resveratrol on PEPCK was studied. In the present study, PEPCK activity was significantly increased in STZ treated group as compared with the control group and significantly decreased upon resveratrol treatment with no significant difference with the control group. These results came in agreement with Anand et al., 2010 (25) concluded that sustained hyperglycemia diminishes the ability of glucose to inhibit gluconeogenesis and PEPCK gene expression and augments hormone-induced PEPCK gene expression.The effect of resveratrol on PI3K-Akt-signaling pathway not only decrease the plasma glucose of insulin-deficient STZ-diabetic rats, but also, could contribute to its lowering effect on hepatic PEPCK level.
(8)
Apart from the hypoglycemic effect of resveratrol, another metabolic consequence is demonstrated in this study, in which liver glycogen was significantly increased upon resveratrol treatment, which may be due to increase glycogen synthase or due to reduced glycogen phosphorylase activities in the liver of diabetic rats with a concomitant increase in liver glycogen stores (11) . So, resveratrol may induce glucose utilization by conversion of glucose into glycogen, although the exact mechanism was not elucidated.
As regards DPP-4 activity in the current study, its activity was significantly increased in STZ induced diabetic rats as compared with control group. In various published clinical reports over the last decade, circulating DPP-4 activity has been reported to be either examined the role of DPP-4 in the development of diabetes, dyslipidaemia and renal dysfunction induced by STZ and found that plasma DPP-4 activity increased progressively with time after STZ treatment in wild-type rats and it was positively correlated to blood glucose.
Finally, the increased activity of plasma DPP-4 could still worsen hyperglycaemia since DPP-4 activation may lead to decrease in the anti-diabetic effects of GLP-1 and GIP; therefore, it was supposed that DPP-4 inhibition was effective in ameliorating STZ-induced metabolic abnormalities (31) . In the present study upon resveratrol treatment, serum DPP-4 activity was significantly decreased as compared with diabetic group but with no significant difference between it and control group.
To our knowledge, this is the first study studied the effect of resveratrol on DPP-4 in STZ induced diabetic rats. The down-regulation mechanism of resveratrol on DPP-4 may be mediated by a novel cell-surface mechanism that induces an increase in protein tyrosine phosphatase activity that may lead to a decrease in the tyrosine phosphorylation of ERK1/2 MAPK resulting in inhibition of Akt kinase and Erk1/2 MAPK that in turn links to the decline in DPP-4 mRNA and protein (32,33) . In the present study, serum DPP-4 and liver PEPCK activity were significantly positively correlated with final fasting serum glucose level and significantly negatively correlated with serum insulin level. These results came in agreement with Kirino et al., 2009(30) who demonstrated that plasma DPP-4 activity levels correlate positively with plasma glucose and HbAlc and negatively with plasma insulin levels, raising the possibility that endogenous DPP-4 activity may influence glucose homeostasis by altering the levels of intact (insulinotropic) incretin hormones
In the present study an insignificant gain in body weight was observed upon resveratrol treatment to diabetic group similar to Palsamy and Subramanian 2008
(9) who suggested that the improvement in body weight gain in diabetic rats supplemented with resveratrol may be due to improvement of sugar and lipid metabolism in these animals.
CONCLUSION
the antihyperglycemic effect of resveratrol may be related to its stimulatory effect on insulin, its suppressive effect on: either DPP-4, so increases the level of incretins with subsequent increase in insulin release followed by lowering blood glucose level, or its inhibitory effect on PEPCK enzyme activity and subsequent decrease in gluconeogenesis, or, finally its stimulation of glucose utilization by increasing glycogen formation.
Recommendation
Further studies are needed to determine, the effect of resveratrol on PEPCK and DPP-IV gene expression to confirm its inhibitory effect at the level of the gene. 
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